PCK2 and polycystic ovary syndrome: The higher binding affinity of these ligands compared to metformin indicated higher inhibitory activities to the overexpression of PEPCK, α-amylase, β-glucosidase, and FBPase and thereby serve as potential novel therapeutic targets for insulin resistance treatment associated with PCOS.